Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14203088 | 1.00 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3HRH1 | |
| Hydrochloric Acid SCHEMBL5042315 | 0.99 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3HRH1 | |
| SCHEMBL14203093 | 0.91 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HRH1 | |
| SCHEMBL14580287 | 0.91 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HRH1 | |
| Hydrochloric Acid SCHEMBL5042333 | 0.90 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3HRH1 | |
| SCHEMBL14203042 | 0.89 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3HRH1 | |
| SCHEMBL8284140 | 0.88 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3HRH1 | |
| Hydrochloric Acid SCHEMBL5038400 | 0.87 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3HRH1 | |
| Hydrochloric Acid SCHEMBL5440843 | 0.87 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3HRH1 | |
| Hydrochloric Acid SCHEMBL5038399 | 0.87 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 3/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.